Drugs / 5-fluouracil
5-fluouracil
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03577704 | Aug 2018 → Sep 2022 | cancer | Shanghai Henlius Biotech | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04617457 | Oct 2021 → Dec 2024 | malignant pancreatic neoplasm, metastatic neoplasm | University of Cologne | Unknown | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT04469556 Comparator | Oct 2020 → Mar 2025 | pancreatic ductal adenocarcinoma | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 2/3 | NCT03344068 Background | Jan 2018 → Dec 2020 | nasopharyngeal carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 4 | NCT01588990 Background | Jun 2012 → Sep 2016 | colorectal cancer | Hoffmann-La Roche | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2017-05-17 | Oncolytics Biotech | Results Oncolytics Biotech® Announces ASCO Abstracts and Preliminary Data for Studies in Pancreatic and Prostate Cancers oncolyticsbiotech.com ↗
Three of five efficacy evaluable patients showed a tumor response (secondary endpoint), with one having a partial response (six-month duration) and two having stable disease (lasting 126 and 221 days). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-05-17 | Oncolytics Biotech | Oncolytics Biotech® Announces ASCO Abstracts and Preliminary Data for Studies in Pancreatic and Prostate Cancers oncolyticsbiotech.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 5-fluouracil | “mFOLFOX6 protocol: oxaliplatin (85 mg/m2), leucovorin (400 mg/m2), and 5-fluouracil (5-FU) (400 mg/m2, followed by 2400 mg/m2), every 2 weeks.” NCT03577704 ↗4“Modified FOLFIRINOX (Folinic acid/Leucovorin, 5-Fluouracil, Irinotecan, Oxaliplatin) administered intravenously.” NCT04469556 ↗ “Nedaplatin 80mg/m2 d1+5-fluouracil 500mg/m2 d2-5, every 3 weeks; a total of 2-3 cycles.” NCT03344068 ↗ |
| Known as | 5-fluouracil (5-FU) | “5-fluouracil (5-FU)” NCT04617457 ↗ |
| Known as | 5-FU | “mFOLFOX6 protocol: oxaliplatin (85 mg/m2), leucovorin (400 mg/m2), and 5-fluouracil (5-FU) (400 mg/m2, followed by 2400 mg/m2), every 2 weeks.” NCT03577704 ↗ |
| Route | Intravenous | “400 mg/m\^2 IV” NCT01588990 ↗ |